EDGEWISE THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

EDGEWISE THERAPEUTICS INC share price today is $29.05, up -3.29%. The stock opened at $30.2 against the previous close of $30.05, with an intraday high of $30.27 and low of $28.89.

EDGEWISE THERAPEUTICS INC Share Price Chart

EDGEWISE THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

EDGEWISE THERAPEUTICS INC Share Price Performance

$29.05 -0.0329(-3.29%) EWTX at 23 Mar 2026 12:57 PM Biotechnology
Lowest Today 28.89
Highest Today 30.27
Today’s Open 30.2
Prev. Close 30.05
52 Week High 31.82
52 Week Low 10.60
Day’s Range: Low 28.89 High 30.27
52-Week Range: Low 10.60 High 31.82
1 day return -
1 Week return -2.35
1 month return -3.29
3 month return +38.94
6 month return +92.32
1 year return +24.18
3 year return +326.09
5 year return -4.5
10 year return -

EDGEWISE THERAPEUTICS INC Institutional Holdings

Orbimed Advisors, LLC 14.47

RA Capital Management, LLC 9.72

Baker Bros Advisors LP 6.13

Paradigm Biocapital Advisors LP 6.10

BlackRock Inc 5.92

Novo A/S 4.99

BRAIDWELL LP 4.86

HHG PLC 4.64

Vanguard Group Inc 4.54

Siren, L.L.C. 4.22

Driehaus Capital Management LLC 3.91

Cormorant Asset Management, LLC 3.74

Perceptive Advisors LLC 3.54

Vanguard Total Stock Mkt Idx Inv 2.65

BB Biotech AG Ord 2.59

Geode Capital Management, LLC 1.63

MPM Oncology Impact Management LP 1.60

State Street Corp 1.58

iShares Russell 2000 ETF 1.53

First Light Asset Management, LLC 1.47

Bellevue Group AG 1.42

Integral Health Asset Management, LLC 1.40

Dimensional Fund Advisors, Inc. 1.13

American Century Small Cap Growth Inv 0.81

American Century U.S. Small Cap Growth 0.81

Fidelity Select Biotechnology 0.76

Vanguard Institutional Extnd Mkt Idx Tr 0.75

Victory Pioneer Select Mid Cap Growth A 0.62

Fidelity Small Cap Index 0.62

Janus Henderson Global Life Sciences 0.58

Janus Henderson Global Life Sciences D 0.58

Janus Henderson Glb Life Scn I2 USD 0.53

iShares Biotechnology ETF 0.53

Eventide Healthcare & Life Sciences I 0.53

iShares Russell 2000 Growth ETF 0.52

Janus Global Life Science AUSD 0.50

abrdn Healthcare Investors 0.48

Candriam Eqs L Biotech C USD Cap 0.47

Heptagon Driehaus US Micro Cap Eq C$ Acc 0.45

Driehaus Small Cap Growth Institutional 0.42

EDGEWISE THERAPEUTICS INC Market Status

Strong Buy: 5

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 0

EDGEWISE THERAPEUTICS INC Fundamentals

Market Cap 3117.28 M

PB Ratio 5.9648

PE Ratio 0.0

Enterprise Value 2589.02 M

Total Assets 552.60 M

Volume 1004175

EDGEWISE THERAPEUTICS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-89435000 -89.4M, FY22:-15397000 -15.4M, FY21:-42139000 -42.1M, FY20:-17054000 -17.1M, FY19:-9486000 -9.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-567000 -0.6M, Q1/2025:-554000 -0.6M, Q3/2024:null 0.0M, Q2/2024:-534000 -0.5M

Quarterly Net worth Q3/2025:-40666000 -40.7M, Q2/2025:-36115000 -36.1M, Q1/2025:-40798000 -40.8M, Q3/2024:-34129000 -34.1M, Q2/2024:-31497000 -31.5M

About EDGEWISE THERAPEUTICS INC & investment objective

Company Information Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Organisation Biotechnology

Employees 146

Industry Biotechnology

CEO Dr. Kevin Koch Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

EDGEWISE THERAPEUTICS INC FAQs

What is the share price of EDGEWISE THERAPEUTICS INC today?

The current share price of EDGEWISE THERAPEUTICS INC is $29.05.

Can I buy EDGEWISE THERAPEUTICS INC shares in India?

Yes, Indian investors can buy EDGEWISE THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy EDGEWISE THERAPEUTICS INC shares in India?

You can easily invest in EDGEWISE THERAPEUTICS INC shares from India by:

Can I buy fractional shares of EDGEWISE THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of EDGEWISE THERAPEUTICS INC?

EDGEWISE THERAPEUTICS INC has a market cap of $3117.28 M.

In which sector does EDGEWISE THERAPEUTICS INC belong?

EDGEWISE THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in EDGEWISE THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of EDGEWISE THERAPEUTICS INC?

The PE ratio of EDGEWISE THERAPEUTICS INC is N/A and the PB ratio is 5.96.